Neumora Therapeutics, Inc. (NMRA)
(Real Time Quote from BATS)
$12.04 USD
+0.21 (1.78%)
Updated Sep 13, 2024 10:30 AM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Neumora Therapeutics, Inc. (NMRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$23.14 | $29.00 | $18.00 | 95.60% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Neumora Therapeutics, Inc. comes to $23.14. The forecasts range from a low of $18.00 to a high of $29.00. The average price target represents an increase of 95.6% from the last closing price of $11.83.
Analyst Price Targets (7 )
Broker Rating
Neumora Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 75% and 25% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 5 |
Buy | 2 | 2 | 2 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.25 | 1.25 | 1.14 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/28/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
8/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/22/2024 | Needham & Company | Ami Fadia | Not Available | Moderate Buy |
7/8/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Not Available | Strong Buy |
6/17/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/15/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.25 |
# of Recs in ABR | 8 |
Average Target Price | $23.14 |
LT Growth Rate | 29.50% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.39 |
NMRA FAQs
Neumora Therapeutics, Inc. (NMRA) currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 8 brokerage firms.
The average price target for Neumora Therapeutics, Inc. (NMRA) is $23.14. The current on short-term price targets is based on 4 reports.
The forecasts for Neumora Therapeutics, Inc. (NMRA) range from a low of $18 to a high of $29. The average price target represents a increase of $95.60 from the last closing price of $11.83.
The current UPSIDE for Neumora Therapeutics, Inc. (NMRA) is 95.60%
Based on short-term price targets offered by seven analysts, the average price target for Neumora Therapeutics, Inc. comes to $23.14. The forecasts range from a low of $18.00 to a high of $29.00. The average price target represents an increase of 95.6% from the last closing price of $11.83.